GlassScriptPhysician profile
Laurie E Cochran
NPI 1043483001
$8,516.30
in general payments reported to CMS, 2019-2025
40 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $1,186 · 2021: $1,243 · 2022: $1,052 · 2023: $1,414 · 2024: $1,648 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,983 · Education: $70.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,983.17 |
| Education | $70.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,007.38 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $978.13 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $945.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $725.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $496.09 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $351.11 | 2021-2025 | Vraylar |
| Amgen INC. | $346.75 | 2020-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $328.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $308.22 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.52 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Tris Pharma INC | $230.36 | 2019-2024 | Dyanavel Xr |
| Sumitomo Pharma America, INC. | $205.97 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $193.22 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.47 | 2020-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $177.74 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.